8.085
전일 마감가:
$7.71
열려 있는:
$7.8
하루 거래량:
656.85K
Relative Volume:
0.63
시가총액:
$847.79M
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-2.6165
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
+0.44%
1개월 성능:
-10.00%
6개월 성능:
-52.11%
1년 성능:
-45.19%
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RCUS
Arcus Biosciences Inc
|
8.08 | 847.79M | 247.00M | -249.00M | -267.00M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
488.05 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.76 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.48 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.78 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
253.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2024-10-21 | 개시 | H.C. Wainwright | Neutral |
2024-10-08 | 개시 | Wells Fargo | Overweight |
2022-11-18 | 개시 | BofA Securities | Neutral |
2022-10-11 | 개시 | Morgan Stanley | Overweight |
2021-10-15 | 재개 | BTIG Research | Buy |
2020-11-24 | 개시 | Berenberg | Buy |
2020-11-23 | 개시 | Evercore ISI | Outperform |
2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
2020-03-04 | 개시 | Barclays | Overweight |
2019-11-12 | 개시 | SunTrust | Buy |
2019-09-27 | 개시 | Mizuho | Buy |
2019-05-24 | 재개 | Citigroup | Buy |
2018-10-09 | 개시 | Wedbush | Outperform |
2018-04-09 | 개시 | Citigroup | Buy |
2018-04-09 | 개시 | Goldman | Neutral |
2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Geode Capital Management LLC Decreases Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Certain restricted stock units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Options of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Alliancebernstein L.P. - Defense World
Vanguard Group Inc. Sells 79,539 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Corebridge Financial Inc. Sells 2,258 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
American Century Companies Inc. Increases Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies - Investing.com Australia
Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies By Investing.com - Investing.com South Africa
Arcus Biosciences' SWOT analysis: biotech stock's potential in cancer therapies - Investing.com
RCUS stock touches 52-week low at $7.5 amid market challenges - Investing.com
RCUS stock touches 52-week low at $7.5 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
(RCUS) Trading Signals - news.stocktradersdaily.com
Institutional owners may consider drastic measures as Arcus Biosciences, Inc.'s (NYSE:RCUS) recent US$134m drop adds to long-term losses - simplywall.st
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo
RCUS stock touches 52-week low at $8.81 amid market challenges - Investing.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Amundi - Defense World
RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month - Insider Monkey
RCUS FY2025 EPS Estimate Raised by Cantor Fitzgerald - Defense World
Arcus Biosciences at Barclays Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Top 10 Insider Purchases Last Month - Insider Monkey
(RCUS) Investment Analysis - Stock Traders Daily
Arcus Biosciences at Leerink’s Global Healthcare Conference: Strategic Advancements By Investing.com - Investing.com Canada
RCUS stock touches 52-week low at $9.42 amid market challenges - Investing.com Australia
Terry Rosen Increases Stake in Arcus Biosciences Inc (RCUS) with Recent Share Purchase - GuruFocus.com
Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding - Simply Wall St
Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares - Yahoo
Learn to Evaluate (RCUS) using the Charts - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Upgraded at HC Wainwright - Defense World
Wedbush Forecasts Arcus Biosciences’ Q1 Earnings (NYSE:RCUS) - Defense World
Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares By Investing.com - Investing.com South Africa
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo
What is Leerink Partnrs’ Forecast for RCUS Q1 Earnings? - Defense World
Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock - Investing.com Australia
Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock By Investing.com - Investing.com South Africa
Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares - Investing.com India
Arcus Biosciences Executives Increase Their Holdings - TradingView
RCUS stock touches 52-week low at $9.88 amid market challenges - Investing.com
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):